Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: CKD-508 Tablet
Drug: Placebo Tablet
Drug: Placebo Capsule
Drug: CKD-508 Capsule

First Posted Date: 2020-07-28

Last Posted Date: 2024-02-15

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 88

Registration Number: NCT04488900

Locations: 🇬🇧
Northwick Park Hospital, Harrow, Middlesex, United Kingdom

Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers

Phase 1

Conditions: Cardiovascular Disease

Interventions: Drug: CKD-330 Tab. and D086 Tab.
Drug: CKD-333 Tab.

First Posted Date: 2020-07-20

Last Posted Date: 2020-07-22

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 51

Registration Number: NCT04478097

Locations: 🇰🇷
Jang Hee Hong, Daejeon, Korea, Republic of

Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients.

Phase 4

Conditions: Liver Transplant

Interventions: Drug: Everolimus Tab.
Drug: Mycophenolate mofetil Tab./Cap.

First Posted Date: 2020-07-15

Last Posted Date: 2020-07-15

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 150

Registration Number: NCT04471441

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

A Clinical Study to Evaluate the Efficacy and Safety of CKD-351

Phase 2

Conditions: Primary Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: CKD-351
Drug: Latanoprost+Dorzolmamide

First Posted Date: 2020-06-25

Last Posted Date: 2020-06-25

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 100

Registration Number: NCT04448223

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: D759, D150
Drug: CKD 501
Drug: CKD-501, D759, D150

First Posted Date: 2020-06-16

Last Posted Date: 2020-11-16

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 48

Registration Number: NCT04431687

Locations: 🇰🇷
CHA Bundang Medical Center, CHA University, Seongnam-si, Bundang, Korea, Republic of

Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet

Phase 3

Conditions: Hypertension
Dyslipidemias

Interventions: Drug: CKD-828
Drug: CKD-828(placebo)
Drug: D326
Drug: D326(placebo)
Drug: D337
Drug: D337(placebo)
Drug: D013(placebo)
Drug: D013

First Posted Date: 2020-05-14

Last Posted Date: 2020-05-14

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 120

Registration Number: NCT04388215

Locations: 🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

Compare the Pharmacokinetics and Safety of CKD-391

Phase 1

Completed

Conditions: Hyperlipidemias

Interventions: Drug: CKD-391 10/10mg
Drug: D090, D337

First Posted Date: 2020-04-21

Last Posted Date: 2020-04-21

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 44

Registration Number: NCT04354987

Locations: 🇰🇷
Jae-Yong Chung, Gyeonggi-do, Seongnam-si, Korea, Republic of

A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150

Phase 1

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: CKD-501
Drug: D745, D150
Drug: CKD-501, D745, D150

First Posted Date: 2020-04-06

Last Posted Date: 2020-10-30

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 48

Registration Number: NCT04334213

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-389

Phase 1

Conditions: Type 2 Diabetes

Interventions: Drug: Reference drug
Drug: Test drug

First Posted Date: 2020-03-26

Last Posted Date: 2020-03-26

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 34

Registration Number: NCT04322032

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

Phase 3

Completed

Conditions: Dyslipidemia Patients With Hypertension

Interventions: Drug: D013, D326, D337
Drug: placebo of D013, D326, D337
Drug: D013, placebo of D326, placebo of D337

First Posted Date: 2020-03-18

Last Posted Date: 2021-07-28

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 100

Registration Number: NCT04312698

Locations: 🇰🇷
Yonsei University Medical Center Severance Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy